Search

Search Results

1. Chromatin profile-based identification of a novel ER-positive breast cancer subgroup with reduced ER-responsive element accessibility

   Background

   Oestrogen receptor (ER) signalling-dependent cancer cell growth is one of the major features of ER-positive breast cancer (BC). Inhibition...

   Kohei Kumegawa, Sumito Saeki, ... Reo Maruyama in British Journal of Cancer

   Article Open access 01 February 2023
   

2. ER-positive and BRCA2-mutated breast cancer: a literature review

   BRCA2 -mutated carriers have a high lifetime risk of breast cancer (BC), an early age of onset, and an increased risk of other cancers (including...

   Pu-Chun Li, Yi-Fan Zhu, ... Bei Li in European Journal of Medical Research

   Article Open access 06 January 2024
   

3. AGR2 and FOXA1 as prognostic markers in ER-positive breast cancer

   Background

   The prognostic role of either forkhead box A1 (FOXA1) or anterior gradient 2 (AGR2) in breast cancer has been found separately. Considering...

   Meng Zhou, **ng-li Gan, ... Ze-fang Ren in BMC Cancer

   Article Open access 11 August 2023
   

4. Palbociclib sensitizes ER-positive breast cancer cells to fulvestrant by promoting the ubiquitin-mediated degradation of ER-α via SNHG17/Hippo-YAP axis

   Purpose

   Endocrine therapy is the anti-tumor therapy for human breast cancer but endocrine resistance was a major burden. It has been reported that...

   Lei Lei, Yuan Huang, ... Yabing Zheng in Breast Cancer Research and Treatment

   Article Open access 04 November 2023
   

5. Prognostic model of ER-positive, HER2-negative breast cancer predicted by clinically relevant indicators

   Purpose

   To study the clinicopathological variables connected with disease-free survival (DFS) as well as overall survival (OS) in patients who are...

   **nming Song, Pintian Wang, ... **g Lin in Clinical and Translational Oncology

   Article 15 September 2023
   

6. Prognosis and influencing factors of ER-positive, HER2-low breast cancer patients with residual disease after neoadjuvant chemotherapy: a retrospective study

   Previously, we found that patients with estrogen receptor (ER)-positive, HER2-low breast cancer are resistant to neoadjuvant chemotherapy (NACT) and...

   Lingfeng Tang, Linshan Jiang, ... Shengchun Liu in Scientific Reports

   Article Open access 23 May 2024
   

7. Tafazzin mediates tamoxifen resistance by regulating cellular phospholipid composition in ER-positive breast cancer

   Tamoxifen is the frontline therapeutic agent for the estrogen receptor-positive (ER + ) subtype of breast cancer patients, which accounts for 70–80%...

   Xuan Li, Yuan Zhang, ... Hanqiu Zheng in Cancer Gene Therapy

   Article 07 November 2023
   

8. Lasofoxifene as a potential treatment for aromatase inhibitor-resistant ER-positive breast cancer

   Background

   Breast cancers treated with aromatase inhibitors (AIs) can develop AI resistance, which is often driven by estrogen receptor-alpha (ERα/ ESR1...

   Muriel Lainé, Marianne E Greene, ... Geoffrey L Greene in Breast Cancer Research

   Article Open access 07 June 2024
   

9. Nodal pCR and overall survival following neoadjuvant chemotherapy for node positive ER+/Her2- breast cancer

   Purpose

   The role of neoadjuvant chemotherapy (NAC) in node-positive (N+) ER+/HER2- breast cancer (BC) is debated, given low total pathologic complete...

   Dan Moldoveanu, Tanya L. Hoskin, ... Judy C. Boughey in Breast Cancer Research and Treatment

   Article 25 October 2023
   

10. Molecular differences between younger versus older ER-positive and HER2-negative breast cancers

    The RxPONDER and TAILORx trials demonstrated benefit from adjuvant chemotherapy in patients age ≤ 50 with node-positive breast cancer and Recurrence...

    Tao Qing, Thomas Karn, ... Lajos Pusztai in npj Breast Cancer

    Article Open access 07 November 2022
    

11. RBCK1 regulates the progression of ER-positive breast cancer through the HIF1α signaling

    Breast cancer is the most common malignancy in women on a global scale. It can generally be divided into four main categories, of which estrogen...

    Zhiguo Niu, Jianing Fan, ... Qingsong Huang in Cell Death & Disease

    Article Open access 06 December 2022
    

12. PET/MRI of hypoxia and vascular function in ER-positive breast cancer: correlations with immunohistochemistry

    Objectives

    To explore the relationship between indices of hypoxia and vascular function from ¹⁸ F-fluoromisonidazole ([ ¹⁸ F]-FMISO)-PET/MRI with...

    Julia C. Carmona-Bozo, Roido Manavaki, ... Fiona J. Gilbert in European Radiology

    Article Open access 11 May 2023
    

13. PR status is a more decisive factor in efficacy of adding pertuzumab into neoadjuvant therapy for HER2-positive and lymph node-positive breast cancer than ER status: a real-world retrospective study in China

    Background

    Although neoadjuvant trastuzumab and pertuzumab (HP)-based regimens are recommended for human epidermal receptor-positive (HER2 +)/lymph...

    **aoyu Liu, Zhaoyun Liu, ... Zhiyong Yu in World Journal of Surgical Oncology

    Article Open access 18 September 2023
    

14. Unbalanced bidirectional causal association between thyroid cancer and ER-positive breast cancer: should we recommend screening for thyroid cancer in breast cancer patients?

    Background

    The association between breast cancer (BC) and thyroid cancer (TC) has been studied in several epidemiological studies. However, the...

    Hongtao Wang, Shiwen Li, ... Fan Zhang in BMC Genomics

    Article Open access 11 December 2023
    

15. High-fat diet promotes tumor growth in the patient-derived orthotopic xenograft (PDOX) mouse model of ER positive endometrial cancer

    Endometrial cancer, one of the common gynecological malignancies, is affected by several influencing factors. This study established a unique...

    Ke Shen, Dandan Shen, ... Li Yang in Scientific Reports

    Article Open access 02 October 2023
    

16. Estrogen-dependent activation of NCOA3 couples with p300 and NF-κB to mediate antiapoptotic genes in ER-positive breast cancer cells

    Circumvention of apoptosis by the elevation of antiapoptotic proteins is an important cause of carcinogenesis. The induction of antiapoptotic genes,...

    Jun Wang, Zhiyong Zhou in Discover Oncology

    Article Open access 28 February 2023
    

17. Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models

    Endocrine therapy (ET) is an effective first-line therapy for women with estrogen receptor-positive (ER + ) breast cancers. While both ionizing...

    Anna R. Michmerhuizen, Lynn M. Lerner, ... Corey W. Speers in npj Breast Cancer

    Article Open access 10 March 2022
    

18. Head-to-head comparison of ¹⁸F-FDG and ¹⁸F-FES PET/CT for initial staging of ER-positive breast cancer patients

    Purpose

    To compare the diagnostic performance of ¹⁸ F-fluorodeoxyglucose ( ¹⁸ F-FDG) and ¹⁸ F-fluoroestradiol ( ¹⁸ F-FES) positron emission...

    Peerapon Kiatkittikul, Supanida Mayurasakorn, ... Chanisa Chotipanich in European Journal of Hybrid Imaging

    Article Open access 18 December 2023
    

19. Comprehensive analysis of a cuproptosis-related ceRNA network implicates a potential endocrine therapy resistance mechanism in ER-positive breast cancer

    Background

    While adjuvant endocrine therapy (ET) may decrease the mortality rate of estrogen receptor-positive (ER+) breast cancer (BC), the...

    Dongni Zhang, Wen** Lu, ... Mengfan Zhang in BMC Medical Genomics

    Article Open access 05 May 2023
    

20. RB loss determines selective resistance and novel vulnerabilities in ER-positive breast cancer models

    The management of metastatic estrogen receptor (ER) positive HER2 negative breast cancer (ER+) has improved; however, therapeutic resistance and...

    Vishnu Kumarasamy, Ram Nambiar, ... Erik S. Knudsen in Oncogene

    Article 09 June 2022